RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Perspective: Issues with Proposed Regulatory Pathways for Follow-on Biologics

Perspective: Issues with Proposed Regulatory Pathways for Follow-on Biologics

Posted 01 August 2011

Most small molecule drugs are produced through some chemical synthesis steps and purified through a rigorous process. This enables production of substantially pure active pharmaceutical ingredient (API), which is characterized further by various physical and chemical methods.

 

© 2022 Regulatory Affairs Professionals Society.